Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Avidity Biosciences (RNA) Leases (2020 - 2025)

Avidity Biosciences (RNA) has disclosed Leases for 6 consecutive years, with $51.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases rose 812.58% year-over-year to $51.3 million, compared with a TTM value of $51.3 million through Dec 2025, up 812.58%, and an annual FY2025 reading of $51.3 million, up 812.58% over the prior year.
  • Leases was $51.3 million for Q4 2025 at Avidity Biosciences, down from $52.8 million in the prior quarter.
  • Across five years, Leases topped out at $52.8 million in Q3 2025 and bottomed at $45000.0 in Q3 2021.
  • Average Leases over 5 years is $11.1 million, with a median of $8.0 million recorded in 2023.
  • The sharpest move saw Leases crashed 87.94% in 2021, then soared 20486.67% in 2022.
  • Year by year, Leases stood at $10.8 million in 2021, then fell by 18.81% to $8.8 million in 2022, then decreased by 5.53% to $8.3 million in 2023, then tumbled by 32.06% to $5.6 million in 2024, then surged by 812.58% to $51.3 million in 2025.
  • Business Quant data shows Leases for RNA at $51.3 million in Q4 2025, $52.8 million in Q3 2025, and $4.2 million in Q2 2025.